AstraZeneca’s COVID-19 vaccine may receive EUA from India soon

By Nikita Chaurasia  Date: 2020-12-24

AstraZeneca’s COVID-19 vaccine may receive EUA from India soon

Reportedly, India intends to grant emergency use authorization (EUA) to Oxford/AstraZeneca’s coronavirus vaccine by next week, following submission of some additional data to the concerned authorities by a few local manufacturers. India could be the first country to approve AstraZeneca’s vaccine as the British drugmaker continues the process of examining data from its clinical trials.

Being the biggest vaccine-making country worldwide, India intends to begin immunizing the population starting next month and is in talks of approving EUA applications for Coronavirus vaccines made by local company Bharat Biotech as well as the American pharmaceutical giant Pfizer Inc., claimed trusted sources.

In this context, experts cite that the AstraZeneca-Oxford COVID-19 shot is essential in countries with lower-income and hot climatic conditions as it is inexpensive, easy to transport, and can be stored at normal fridge temperatures for long periods.

The Central Drugs Standard Control Organization (CDSCO) of India had initially assessed the three applications on 9th December and requested more information from all the pharmaceutical firms, including Serum Institute of India (SII), the company which is reportedly producing the AstraZeneca vaccines.

Although Serum Institute has provided all the data required, the authorities are reportedly awaiting information from Pfizer, and some additional information from Bharat Biotech, sources confirmed.

According to the data released by AstraZeneca of their late-stage trials in Brazil and in the U.K., the vaccine showed 62% efficacy among trial participants who were given two dosages each, and 90% efficacy for a smaller group of people given first a half, and then a full dosage, which evidently forms the base of the anticipated approval.

If sources are to be believed, only two full-dose regimens of the COVID-19 vaccine are being considered by the Indian regulator despite its lower success rate.

India is yet to sign a vaccine supply agreement with any pharmaceutical company; however, Serum Institute has reportedly stockpiled over 50 million doses of the AstraZeneca vaccines and intends to make a total of 400 million doses by July 2021, cited sources knowledgeable with the matter.

Source Credits –

https://in.reuters.com/article/uk-health-coronavirus-india-vaccine-excl/exclusive-india-likely-to-approve-astrazeneca-vaccine-by-next-week-sources-idINKBN28W27I

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW Group to opt for green steel in vehicle production from 2025

BMW Group to opt for green steel in vehicle production from 2025

By Nikita Chaurasia

As climatic changes and other environmental issues take center stage, the BMW Group, to minimize carbon dioxide (CO2) emissions at the core of its supply chain, has reportedly agreed to use green steel from Swedish firm H2 Green Steel beginning in 20...

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...